Conduit Pharmaceuticals (CDT) Competitors $2.80 +0.01 (+0.36%) Closing price 04:00 PM EasternExtended Trading$2.73 -0.07 (-2.50%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CDT vs. GNPX, PMCB, AIM, SLXN, TCRT, OMGA, INAB, HCWB, SBFM, and CDIOShould you be buying Conduit Pharmaceuticals stock or one of its competitors? The main competitors of Conduit Pharmaceuticals include GENPREX (GNPX), Nuvilex (PMCB), AIM ImmunoTech (AIM), Silexion Therapeutics (SLXN), Alaunos Therapeutics (TCRT), Omega Therapeutics (OMGA), IN8bio (INAB), HCW Biologics (HCWB), Sunshine Biopharma (SBFM), and Cardio Diagnostics (CDIO). These companies are all part of the "pharmaceutical products" industry. Conduit Pharmaceuticals vs. Its Competitors GENPREX Nuvilex AIM ImmunoTech Silexion Therapeutics Alaunos Therapeutics Omega Therapeutics IN8bio HCW Biologics Sunshine Biopharma Cardio Diagnostics Conduit Pharmaceuticals (NASDAQ:CDT) and GENPREX (NASDAQ:GNPX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability. Which has preferable valuation and earnings, CDT or GNPX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioConduit PharmaceuticalsN/AN/A-$17.80M-$534.48-0.01GENPREXN/AN/A-$21.11MN/AN/A Do analysts recommend CDT or GNPX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Conduit Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00GENPREX 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals believe in CDT or GNPX? 3.3% of Conduit Pharmaceuticals shares are held by institutional investors. Comparatively, 14.1% of GENPREX shares are held by institutional investors. 4.1% of Conduit Pharmaceuticals shares are held by insiders. Comparatively, 8.5% of GENPREX shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer CDT or GNPX? In the previous week, Conduit Pharmaceuticals and Conduit Pharmaceuticals both had 1 articles in the media. GENPREX's average media sentiment score of 1.00 beat Conduit Pharmaceuticals' score of 0.94 indicating that GENPREX is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Conduit Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GENPREX 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, CDT or GNPX? Conduit Pharmaceuticals has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500. Comparatively, GENPREX has a beta of -0.5, meaning that its share price is 150% less volatile than the S&P 500. Is CDT or GNPX more profitable? Conduit Pharmaceuticals' return on equity of 0.00% beat GENPREX's return on equity.Company Net Margins Return on Equity Return on Assets Conduit PharmaceuticalsN/A N/A -435.57% GENPREX N/A -664.65%-370.18% SummaryConduit Pharmaceuticals beats GENPREX on 5 of the 9 factors compared between the two stocks. Get Conduit Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CDT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDT vs. The Competition Export to ExcelMetricConduit PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.23M$2.42B$5.54B$8.87BDividend YieldN/A1.77%5.39%4.10%P/E Ratio-0.018.7226.1719.90Price / SalesN/A663.86414.67113.66Price / CashN/A151.5836.1356.90Price / Book-0.044.548.055.38Net Income-$17.80M$31.16M$3.15B$248.50M7 Day Performance14.29%0.15%1.85%2.97%1 Month Performance-28.93%8.81%4.81%6.02%1 Year Performance-99.79%2.55%34.86%20.39% Conduit Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDTConduit PharmaceuticalsN/A$2.80+0.4%N/A-99.8%$2.23MN/A-0.013GNPXGENPREX1.6895 of 5 stars$0.23-13.2%N/A-85.9%$7.34MN/A0.0020Gap UpHigh Trading VolumePMCBNuvilex1.7598 of 5 stars$1.06flatN/A-41.8%$7.28MN/A1.434Gap DownAIMAIM ImmunoTech1.9465 of 5 stars$9.50+3.1%$275.00+2,794.7%-75.6%$7.26M$146K-20.2120News CoverageSLXNSilexion TherapeuticsN/A$0.82+0.1%$5.00+512.7%N/A$7.08MN/A0.00N/ATCRTAlaunos Therapeutics0.7789 of 5 stars$4.48+4.4%N/A-28.0%$7.03M$10K0.0040News CoverageOMGAOmega Therapeutics2.5844 of 5 stars$0.13-21.8%$8.50+6,700.0%-94.4%$6.92M$8.10M-0.09120Gap UpINABIN8bio3.0196 of 5 stars$2.23+2.3%$180.00+7,971.7%-91.5%$6.59MN/A-0.1620High Trading VolumeHCWBHCW Biologics3.3414 of 5 stars$4.67+2.2%$35.00+649.5%-85.6%$6.58M$2.57M-0.2040News CoverageGap DownSBFMSunshine Biopharma3.2098 of 5 stars$1.43-0.7%$15.00+949.0%+259.9%$6.56M$34.87M-0.013News CoverageCDIOCardio Diagnostics3.2829 of 5 stars$3.70-0.3%$60.00+1,521.6%-77.7%$6.45M$40K0.001 Related Companies and Tools Related Companies GENPREX Alternatives Nuvilex Alternatives AIM ImmunoTech Alternatives Silexion Therapeutics Alternatives Alaunos Therapeutics Alternatives Omega Therapeutics Alternatives IN8bio Alternatives HCW Biologics Alternatives Sunshine Biopharma Alternatives Cardio Diagnostics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDT) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conduit Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Conduit Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CDT Stock Alerts